In 2007, the agency approved Lialda, generically known as mesalamine, for induction of remission in patients with active, mild to moderate ulcerative colitis.
Read the Shire Pharmaceuticals release on Lialda.
Read the FDA statement about Lialda.
Related Articles on FDA Approvals:
FDA Approves Lazanda Nasal Spray for Cancer Pain
FDA Clears New Version of PillCam for Esophageal Mucosa
St. Jude Gets FDA Approval for Epiducer Neurostimulation Delivery System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
